Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mark J. Mulligan, Kirsten E. Lyke, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, Kathleen M. Neuzil, Vanessa Raabe, Ruth Bailey, Kena A. Swanson, Ping Li, Kenneth Koury, Warren V. Kalina, David Cooper, Camila R. Fontes-Garfias, Pei‐Yong Shi, Özlem Türeci, Kristin R. Tompkins, Edward E. Walsh, Robert W. Frenck, Ann R. Falsey, Philip R. Dormitzer, William C. Gruber, Uğur Şahin, Kathrin U. Jansen
Topics & Concepts
ReactogenicityImmunogenicityMedicineTolerabilityVirologyVaccinationPandemicCoronavirusAdverse effectImmunologyCoronavirus disease 2019 (COVID-19)Internal medicinePharmacologyAntibodyDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchRNA Interference and Gene DeliveryAnimal Virus Infections Studies